JPWO2023025307A5 - - Google Patents
Info
- Publication number
- JPWO2023025307A5 JPWO2023025307A5 JP2024513014A JP2024513014A JPWO2023025307A5 JP WO2023025307 A5 JPWO2023025307 A5 JP WO2023025307A5 JP 2024513014 A JP2024513014 A JP 2024513014A JP 2024513014 A JP2024513014 A JP 2024513014A JP WO2023025307 A5 JPWO2023025307 A5 JP WO2023025307A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- optionally substituted
- alkyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111000443 | 2021-08-27 | ||
| CN202111000443.7 | 2021-08-27 | ||
| CN202111447991.4 | 2021-11-30 | ||
| CN202111447991 | 2021-11-30 | ||
| CN202210274490.9 | 2022-03-18 | ||
| CN202210274490 | 2022-03-18 | ||
| PCT/CN2022/115259 WO2023025307A1 (en) | 2021-08-27 | 2022-08-26 | Substituted tricyclic compounds as parp inhibitors and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024531477A JP2024531477A (ja) | 2024-08-29 |
| JPWO2023025307A5 true JPWO2023025307A5 (https=) | 2025-08-20 |
| JP2024531477A5 JP2024531477A5 (https=) | 2025-08-20 |
Family
ID=85322483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513014A Pending JP2024531477A (ja) | 2021-08-27 | 2022-08-26 | Ｐａｒｐ阻害剤としての置換三環式化合物およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240368169A1 (https=) |
| EP (1) | EP4392425A4 (https=) |
| JP (1) | JP2024531477A (https=) |
| KR (1) | KR20240053612A (https=) |
| CN (1) | CN117980307A (https=) |
| AU (1) | AU2022334408A1 (https=) |
| CA (1) | CA3230491A1 (https=) |
| IL (1) | IL311024A (https=) |
| MX (1) | MX2024002425A (https=) |
| WO (1) | WO2023025307A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230159525A1 (en) | 2021-10-01 | 2023-05-25 | Xinthera, Inc. | Azetidine and pyrrolidine parp1 inhibitors and uses thereof |
| AU2023209820B2 (en) | 2022-01-21 | 2024-10-10 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| IL315586A (en) * | 2022-03-11 | 2024-11-01 | Impact Therapeutics Shanghai Inc | Substituted tricyclic compounds as parp inhibitors and the use thereof |
| KR20240161147A (ko) | 2022-03-14 | 2024-11-12 | 슬랩 파마슈티컬스 엘엘씨 | 다중 사이클릭 화합물 |
| FI4497438T3 (fi) | 2022-04-28 | 2025-10-20 | Xinthera Inc | Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja |
| CN119110801A (zh) * | 2022-05-07 | 2024-12-10 | 南京明德新药研发有限公司 | 选择性抑制parp1的氟代喹喔啉酮衍生物 |
| CN115232129B (zh) * | 2022-08-18 | 2023-12-01 | 上海闻耐医药科技有限公司 | 一种parp1选择性抑制剂及其制备方法和用途 |
| CN117263943A (zh) * | 2022-09-09 | 2023-12-22 | 轩竹生物科技股份有限公司 | 聚（adp核糖）聚合酶选择性抑制剂 |
| JP2025538192A (ja) * | 2022-11-10 | 2025-11-26 | 上海海和薬物研究開発股▲ふん▼有限公司 | 縮合三環式ｐａｒｐ１阻害剤、その調製方法、および使用 |
| CN120677162A (zh) * | 2023-06-13 | 2025-09-19 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
| TW202525808A (zh) * | 2023-09-13 | 2025-07-01 | 大陸商上海瑛派藥業有限公司 | 用作ｐａｒｐ１抑制劑的化合物、其用途及包含其之組合物 |
| CN117567473B (zh) * | 2023-11-09 | 2025-07-04 | 中国药科大学 | 一种靶向同源二聚体的抑制剂及其制备方法与应用 |
| AR134686A1 (es) * | 2023-12-13 | 2026-03-04 | Eikon Therapeutics Inc | Síntesis novedosa de compuestos tricíclicos sustituidos |
| CN120923504A (zh) | 2024-05-09 | 2025-11-11 | 上海瑛派药业有限公司 | Parp1抑制剂的晶型及其制备 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| AUPS137402A0 (en) | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| CN101616919B (zh) | 2006-12-28 | 2012-10-10 | 雅培制药有限公司 | 聚（adp核糖）聚合酶抑制剂 |
| CA2716726C (en) | 2008-03-27 | 2017-01-24 | Janssen Pharmaceutica Nv | Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors |
| KR101779137B1 (ko) * | 2009-01-23 | 2017-09-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 폴리(ａｄｐ-리보스)폴리머라제(ｐａｒｐ) 억제제 |
| ES2604305T3 (es) | 2009-07-14 | 2017-03-06 | Nerviano Medical Sciences S.R.L. | 3-oxo-2,3-dihidro-1H-isoindol-4-carboxamida con inhibición selectiva de PARP-1 |
| EP2459561A1 (en) | 2009-07-30 | 2012-06-06 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
| WO2013014038A1 (en) | 2011-07-26 | 2013-01-31 | Nerviano Medical Sciences S.R.L. | 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives as parp-1 inhibitors |
| PH12017502228B1 (en) * | 2015-06-09 | 2022-08-03 | Onconic Therapeutics Inc | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same |
| GB201800733D0 (en) * | 2018-01-17 | 2018-02-28 | Cambridge Entpr Ltd | Cancer |
| MX2022000711A (es) | 2019-07-19 | 2022-02-23 | Astrazeneca Ab | Inhibidores de parp1. |
| US11795158B2 (en) | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| CN112028829B (zh) * | 2020-09-25 | 2022-02-15 | 温州大学 | 一种合成菲啶酮类化合物的方法 |
| TW202309025A (zh) * | 2021-04-19 | 2023-03-01 | 美商辛瑟拉股份有限公司 | Parp1抑制劑及其用途 |
| FI4497438T3 (fi) * | 2022-04-28 | 2025-10-20 | Xinthera Inc | Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja |
-
2022
- 2022-08-26 AU AU2022334408A patent/AU2022334408A1/en active Pending
- 2022-08-26 MX MX2024002425A patent/MX2024002425A/es unknown
- 2022-08-26 KR KR1020247010055A patent/KR20240053612A/ko active Pending
- 2022-08-26 CA CA3230491A patent/CA3230491A1/en active Pending
- 2022-08-26 JP JP2024513014A patent/JP2024531477A/ja active Pending
- 2022-08-26 CN CN202280058269.8A patent/CN117980307A/zh active Pending
- 2022-08-26 WO PCT/CN2022/115259 patent/WO2023025307A1/en not_active Ceased
- 2022-08-26 EP EP22860653.9A patent/EP4392425A4/en active Pending
- 2022-08-26 IL IL311024A patent/IL311024A/en unknown
- 2022-08-26 US US18/687,111 patent/US20240368169A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA126421C2 (uk) | Інгібітори pd-1/pd-l1 | |
| JPWO2023025307A5 (https=) | ||
| WO2024197503A1 (en) | Tricyclic derivatives as kras inhibitors | |
| JP7357637B2 (ja) | ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドの同位体置換体 | |
| CN109310677A (zh) | 通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷 | |
| CN108430473B (zh) | 抗增殖化合物以及其药物组合物和用途 | |
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| CA3068591A1 (en) | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide | |
| KR102936318B1 (ko) | 소세포폐암의 병용 치료용 퀴놀린 유도체 | |
| JP2021528496A5 (https=) | ||
| CN114469949A (zh) | 用于治疗弥漫大b细胞淋巴瘤的喹啉衍生物 | |
| CN111973747A (zh) | 用于联合治疗卵巢癌的喹啉衍生物 | |
| AU2013269994B2 (en) | Solid state forms of N-((S)-2,3-Dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide | |
| CN112043831A (zh) | 用于联合治疗乳腺癌的喹啉类化合物 | |
| CN112121048A (zh) | 用于联合治疗食管癌的喹啉类化合物 | |
| CN118678958A (zh) | 药物组合物及其用途 | |
| JPWO2020095256A5 (https=) | ||
| KR20220128622A (ko) | Ahr-억제제 및 pd1-억제제 항체의 조합물 및 암 치료에서의 그의 용도 | |
| US20260041693A1 (en) | Combination therapy of cdk7 inhibitors with other anti-cancer therapies | |
| EP3973963A1 (en) | Quinoline derivatives for treatment of head and neck cancer | |
| JPWO2023169226A5 (https=) | ||
| CN106456752B (zh) | 癌症治疗剂的组合 | |
| WO2023085367A1 (ja) | Ｇｃｌ阻害剤 | |
| CN113750096A (zh) | 用于治疗外周t细胞淋巴瘤的喹啉衍生物 | |
| JPWO2022218296A5 (https=) |